MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.breast.2026.104720

Медицинская библиотека · Breast (Edinburgh, Scotland) · 2026

Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results.

Popovic Lazar, Barroso-Sousa Romualdo, El Saghir Nagi S, Dent Rebecca, Tuzlali Sitki, Akhtar Saad, Juozaityté Elona, Eglitis Janis, Doval Dinesh C, Castaneda Carlos A, Zirtiloglu Alisan, Hartleben Götz, Deurloo Regula, Toro Paula, Estaytieh Iman, Weber Enya, Mouta João, D'Arrigo Corrado

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The prognostic effect of PD-L1 status in triple-negative breast cancer (TNBC) is uncertain and little is known about PD-L1-positive prevalence and outcomes in the real-world setting.

PATIENTS AND

METHODS

The multicentre retrospective observational VANESSA study evaluated the prevalence and impact of PD-L1-positive status in 2054 patients receiving systemic therapy for early-stage or metastatic (e/m)TNBC between 2014 and 2017. PD-L1 expression was assessed locally and centrally on archival samples. Descriptive analyses of demographic and clinicopathological characteristics, treatment patterns and clinical outcomes (extracted from patients' medical records) according to PD-L1 status were prespecified.

RESULTS

Among 1902 patients with eTNBC, 681 (36%) received neoadjuvant chemotherapy and 1261 (66%) adjuvant chemotherapy. Demographic characteristics were generally similar regardless of PD-L1 status, but lower-risk tumour characteristics were more common in the PD-L1-positive subgroup. Invasive disease-free and overall survival were more favourable in PD-L1-positive eTNBC. In the mTNBC cohort, 120/145 (83%) patients had de novo mTNBC. Median progression-free survival on first-line treatment was 7.6 months (95% CI: 4.1-15.0) in PD-L1-positive mTNBC (n = 30) and 4.9 months (95% CI: 3.6-6.1) in PD-L1-negative mTNBC (n = 83).

CONCLUSION

In eTNBC and mTNBC, PD-L1-positive status was associated with more favourable long-term outcomes, possibly due to tumour-intrinsic characteristics and/or the host immune response. The high proportion with de novo mTNBC may suggest enrolment bias and/or geographic variations in stage at diagnosis.

Для цитирования: Popovic Lazar, Barroso-Sousa Romualdo, El Saghir Nagi S, Dent Rebecca, Tuzlali Sitki, Akhtar Saad, Juozaityté Elona, Eglitis Janis, Doval Dinesh C, Castaneda Carlos A, Zirtiloglu Alisan, Hartleben Götz, Deurloo Regula, Toro Paula, Estaytieh Iman, Weber Enya, Mouta João, D'Arrigo Corrado. Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results.. Breast (Edinburgh, Scotland). 2026. DOI: 10.1016/j.breast.2026.104720.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.